Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00264433 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
A Phase 2 study, sponsored by Adherex Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00264433: Completed Phase 2 study, sponsored by Adherex Technologies.
NCT00264433 is a Phase 2 study that has completed, run by Adherex Technologies. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00264433, a Phase 2 study, has completed, sponsored by Adherex Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with specific incurable, solid tumors with a protein biomarker called N-cadherin. This study will examine the clinical activity of ADH-1.
Interventions
- DRUG ADH -1 (Exherin™)
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00264433 record still lists
NCT00264433 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which ADH -1 (Exherin™) is the first listed.
NCT00264433 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00264433 about?
NCT00264433 is a clinical study titled "A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent". N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with specific incurable, solid tumors with a protein biomarker called N...
What is the current status of trial NCT00264433?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00264433?
The interventions under investigation include: ADH -1 (Exherin™) (DRUG).
Who is sponsoring clinical trial NCT00264433?
This trial is sponsored by Adherex Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.